International Journal of
Medical Science Research and Practice
Vol.**11**, Issue.**4**, pp.**15-21**, December **2024**
E-ISSN: 2349-3186 P-ISSN: 2349-3178
Available online at: www.isroset.org

Review Article

Maternal Screening: A Comprehensive Review of Current Practices, Emerging Technologies, Challenges, and Future Directions

Pawan Kumar[1]

[1]Dept. of Biochemistry, Health Quest Laboratories, Gurugram, Haryana, India

Corresponding Author: pawangaba@gmail.com

Received: 26/Oct/2024; **Accepted**: 28/Nov/2024; **Published**: 31/Dec/2024

Abstract— Maternal screening has evolved into a cornerstone of prenatal care, providing critical insights into the health of both mother and fetus. This comprehensive review examines the current state of maternal screening, encompassing various types of tests, their timing, accuracy, and the ethical considerations surrounding their use. Recent technological advancements, such as non-invasive prenatal testing (NIPT) and expanded carrier screening, are explored alongside their implications for clinical practice.

The review addresses the psychological impact of screening on expectant parents and provides a global perspective on maternal screening practices. By synthesizing current research and expert opinions, this article aims to provide healthcare professionals, researchers, and policymakers with a thorough understanding of the field's present status and future directions. The findings highlight the need for continued research, ethical deliberation, and the development of culturally sensitive guidelines to ensure equitable access to and appropriate use of maternal screening technologies worldwide.

Keywords— Maternal screening, Prenatal care, Non-invasive prenatal testing (NIPT), Carrier screening Genetic screening, Prenatal diagnosis, Pregnancy outcomes.

1. Introduction

Maternal screening has become an important part of prenatal care, offering valuable insights into the health of both the mother and the developing fetus (American College of Obstetricians and Gynecologists [ACOG], 2022). Over the past few decades, advancements in medical technology and genetic research have significantly expanded the scope and accuracy of these screening tests (Allyse et al., 2021). This review article aims to provide a comprehensive overview of current maternal screening practices, their implications, and future directions in this rapidly evolving field.

Maternal screening encompasses a wide range of tests and procedures designed to assess various aspects of maternal and fetal health throughout pregnancy (Salomon et al., 2017). These screenings can detect potential complications, genetic abnormalities, and other health concerns, allowing for early intervention and informed decision-making by healthcare providers and expectant parents (Norton et al., 2022).

The importance of maternal screening in modern obstetric care cannot be overstated. It has contributed significantly to reducing maternal and infant mortality rates worldwide (World Health Organization [WHO], 2022). However, the increasing availability and complexity of screening options also raise important ethical, psychological, and socioeconomic considerations that warrant careful examination (Lewis et al., 2020).

This review will explore the various types of maternal screening tests currently available, their timing and accuracy, and the ethical implications of their use. Additionally, we will discuss recent technological advancements in the field and consider global perspectives on maternal screening practices. By synthesizing current research and expert opinions, this article aims to provide a balanced and informative overview of this critical aspect of prenatal care.

2. Overview of Maternal Screening

Maternal screening involves a series of tests and evaluations performed during pregnancy to monitor the health of both the mother and the developing fetus. These screenings aim to identify potential risks, genetic abnormalities, and other health concerns that may affect the pregnancy or the baby's health after birth (ACOG, 2022).

2.1 Historical Context

The history of maternal screening dates back to the mid-20th century. In the 1950s, the introduction of amniocentesis marked a significant milestone in prenatal diagnosis (Warsof

et al., 2018). The 1970s saw the development of maternal serum alpha-fetoprotein (AFP) screening for neural tube defects, while the 1980s brought about the first trimester combined screening for Down syndrome (Driscoll & Gross, 2009).

2.2 Evolution of Screening Techniques

Over the past few decades, maternal screening has evolved dramatically:

1. 1980s-1990s: Introduction of triple and quad screening tests for chromosomal abnormalities.
2. 2000s: Development of first-trimester combined screening, integrating ultrasound and biochemical markers.
3. 2010s: Introduction of non-invasive prenatal testing (NIPT) using cell-free fetal DNA in maternal blood.
4. 2020s: Advancements in genomic screening and the integration of artificial intelligence in screening methodologies.

2.3 Categories of Maternal Screening

Maternal screening can be broadly categorized into several types:

1. Genetic screening: Assesses the risk of chromosomal abnormalities and inherited disorders.
2. Infectious disease screening: Detects infections that could harm the fetus or complicate pregnancy.
3. Anatomical screening: Uses ultrasound to examine fetal development and detect structural abnormalities.
4. Maternal health screening: Monitors the mother's health, including blood pressure, glucose levels, and other vital parameters.

The implementation of comprehensive maternal screening programs has significantly contributed to improved pregnancy outcomes and reduced infant mortality rates in many countries (WHO, 2022). However, it's important to note that screening tests are not diagnostic; they indicate the likelihood of a condition rather than definitively confirming its presence or absence (Taylor-Phillips et al., 2021).

3. Types of Maternal Screening Tests

3.1 Genetic Screening

Genetic screening has become increasingly sophisticated and accessible in recent years. Key tests include:

3.1.1 Non-Invasive Prenatal Testing (NIPT)

NIPT examines cell-free fetal DNA present in maternal blood to detect common chromosomal abnormalities. With its exceptional sensitivity and specificity, this test has transformed prenatal screening, especially for conditions like Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), and Patau syndrome (trisomy 13). (Gil et al., 2022).

Advantages of NIPT include:

- High accuracy (>99% for trisomy 21)
- Can be performed as early as 10 weeks gestation
- No risk of miscarriage

It is essential to understand that NIPT is a screening tool, not a diagnostic test. Any positive results should be confirmed with diagnostic procedures like amniocentesis or chorionic villus sampling (CVS). (Bianchi & Chiu, 2023).

3.1.2 First Trimester Combined Screening

This screening integrates ultrasound measurements of nuchal translucency with maternal blood tests for pregnancy-associated plasma protein A (PAPP-A) and human chorionic gonadotropin (hCG) to evaluate the risk of chromosomal abnormalities (Norton et al., 2022). Although less precise than NIPT, it offers valuable insights into fetal anatomy and potential pregnancy complications.

3.1.3 Carrier Screening

Carrier screening detects individuals who carry genetic mutations linked to recessive disorders. Expanded carrier screening (ECS) enhances this process by testing for hundreds of genetic conditions at once, enabling a more thorough risk assessment (Henneman et al., 2024).

3.2 Infectious Disease Screening

Screening for infectious diseases is crucial to prevent vertical transmission and manage potential complications. Common tests include:

1. HIV testing: Early detection allows for interventions to reduce mother-to-child transmission.
2. Hepatitis B and C screening: Identifies the need for neonatal vaccination or treatment.
3. Syphilis testing: Early detection and treatment can prevent congenital syphilis.
4. Rubella immunity check: Identifies women at risk of contracting rubella during pregnancy.
5. Group B Streptococcus screening: Guides the use of intrapartum antibiotics to prevent neonatal infection.

The specific panel of tests may vary based on regional prevalence and guidelines (Centers for Disease Control and Prevention [CDC], 2022).

3.3 Anatomical Screening

Ultrasound examinations play a vital role in assessing fetal development and detecting structural abnormalities. Key screenings include:

1. Dating Scan: Performed early in pregnancy to confirm gestational age and viability.
2. Nuchal Translucency Scan: Part of first-trimester combined screening.
3. Anomaly Scan: A detailed examination typically performed around 20 weeks to check fetal anatomy and development.

Recent advancements in ultrasound technology, including 3D and 4D imaging, have improved the detection of fetal anomalies (International Society of Ultrasound in Obstetrics and Gynecology [ISUOG], 2023).

3.4 Maternal Health Screening

Monitoring maternal health is essential for identifying and managing conditions that may affect pregnancy outcomes. Common screenings include:

1. Blood pressure monitoring: For early detection of hypertensive disorders of pregnancy.

2. Gestational diabetes screening: Usually performed between 24-28 weeks of gestation.
3. Complete blood count: To screen for anemia and other hematological disorders.
4. Urinalysis: To detect urinary tract infections and preeclampsia.
5. Thyroid function tests: To identify thyroid disorders that can affect fetal development.

These tests help detect conditions such as preeclampsia, gestational diabetes, anemia, and thyroid disorders that can impact both maternal and fetal health (ACOG, 2024).

4. Timing of Screening Tests During Pregnancy

The timing of maternal screening tests is crucial for their effectiveness and the ability to act on results. Screening typically follows a schedule aligned with key developmental milestones:

4.1 Preconception
- Carrier screening
- Assessment of maternal health, including chronic conditions and immunization status

4.2 First Trimester (Weeks 1-13)
- Dating scan (6-8 weeks)
- First trimester combined screening (11-13 weeks)
- NIPT (from 10 weeks)
- Initial infectious disease screening

4.3 Second Trimester (Weeks 14-26)
- Quad screen (15-20 weeks)
- Anomaly scan (18-22 weeks)
- Gestational diabetes screening (24-28 weeks)

4.4 Third Trimester (Weeks 27-40)
- Group B Streptococcus screening (35-37 weeks)
- Ongoing monitoring of maternal health

This schedule may be adjusted based on individual risk factors or specific healthcare system guidelines (Royal College of Obstetricians and Gynaecologists [RCOG], 2023). It's important to note that some screenings, such as blood pressure monitoring and urine tests, are performed regularly throughout pregnancy.

5. Accuracy and Limitations of Screening Tests

While maternal screening tests have significantly improved in accuracy, it's crucial to understand their limitations:

5.1 Sensitivity and Specificity
Different tests have varying levels of sensitivity (true positive rate) and specificity (true negative rate). For example, NIPT has high sensitivity and specificity for common aneuploidies but may be less accurate for rare conditions (Mackie et al., 2023).

5.2 False Positives and Negatives
All screening tests carry the potential for false results. False positives may cause undue anxiety and lead to unnecessary invasive diagnostic procedures, while false negatives can offer misleading reassurance. The positive predictive value (PPV) of a test varies considerably based on the prevalence of the condition within the screened population (Taylor-Phillips et al., 2021).

5.3 Limitations of Ultrasound
The accuracy of anatomical screening depends on factors such as:
- Fetal position
- Maternal body habitus
- Gestational age
- Operator expertise

Some anomalies may not be detectable until later in pregnancy, and others may be missed even with expert scanning (ISUOG, 2024).

5.4 Evolving Nature of Genetic Testing
As our understanding of genetics expands, the interpretation of results may change over time, potentially leading to reclassification of variants. This can create challenges in counseling and decision-making (Richards et al., 2023).

5.5 Population-Based vs. Individual Risk
Many screening tests provide risk assessments based on population statistics, which may not accurately reflect individual risk. Factors such as family history, ethnicity, and environmental exposures can influence an individual's actual risk (Lee & Park, 2022).
Healthcare providers must communicate these limitations clearly to ensure informed decision-making by expectant parents.

6. Ethical Considerations in Maternal Screening

The rapid advancement of maternal screening technologies has raised several ethical concerns:

6.1 Informed Consent
Ensuring that patients fully understand the implications of screening tests and their potential outcomes is crucial. This includes discussing the possibility of unexpected findings and the limitations of screening tests (World Medical Association, 2023).

6.2 Right Not to Know
Some individuals may prefer not to have certain information about their pregnancy, raising questions about the balance between beneficence and patient autonomy. Healthcare providers must respect a patient's right to decline screening while ensuring they understand the potential consequences of this decision (Ethics Committee of the American Society for Reproductive Medicine, 2024).

6.3 Selective Termination
The ability to detect a wide range of conditions prenatally has led to debates about the ethical implications of selective

termination and its potential impact on disability rights. This raises complex questions about the value of diversity and the definition of a "serious" genetic condition (Kaposy, 2023).

6.4 Incidental Findings
Advanced genetic screening may reveal information unrelated to the primary purpose of the test, such as adult-onset conditions or misattributed paternity. This raises questions about the obligation to disclose such findings and how to handle this information ethically (Green et al., 2022).

6.5 Equity and Access
Disparities in access to advanced screening technologies may exacerbate existing healthcare inequalities. Factors such as socioeconomic status, geographic location, and health literacy can significantly impact access to and understanding of screening options (WHO, 2024).

6.6 Commercialization of Testing
The growing market for direct-to-consumer genetic testing raises concerns about quality control, interpretation of results, and potential misuse of genetic information. There are also concerns about the commodification of pregnancy and the potential for unnecessary anxiety and interventions (Allyse et al., 2023).
Addressing these ethical challenges necessitates continuous collaboration among healthcare professionals, ethicists, policymakers, and the public to establish guidelines that align scientific advancements with ethical principles.

7. Psychological Impact on Expectant Parents

The psychological effects of maternal screening on expectant parents are significant and multifaceted:

7.1 Anxiety and Stress
The waiting period between screening and results can be highly stressful for parents. Studies have shown increased anxiety levels in women undergoing prenatal screening, particularly when faced with high-risk results (Johnson & Lee, 2023). False positive results can cause unnecessary anxiety and may impact the emotional experience of pregnancy (Smith et al., 2022).

7.2 Decision-Making Burden
Parents may face difficult decisions regarding further testing or pregnancy management based on screening results, which can be emotionally taxing. The complexity of genetic information and the probabilistic nature of many screening results can make these decisions particularly challenging (Brown, 2024).

7.3 Reassurance
Negative screening results can provide reassurance and reduce anxiety for many parents. However, it's important to ensure that parents understand that a low-risk result does not guarantee the absence of all possible conditions (Garcia et al., 2023).

7.4 Attachment and Bonding
Early screening, particularly ultrasound examinations, can enhance parental bonding with the fetus. However, concerns about potential abnormalities may complicate this bonding process for some parents (Taylor & Johnson, 2022).

7.5 Cultural and Religious Considerations
Screening results may conflict with cultural or religious beliefs, causing additional stress or ethical dilemmas for some parents. Healthcare providers need to be sensitive to these considerations and provide culturally competent care (Lee et al., 2023).

7.6 Long-term Psychological Effects
The impact of screening can extend beyond pregnancy, influencing parental stress levels and attitudes towards future pregnancies. In cases where a genetic condition is identified, parents may experience grief, guilt, or anxiety about future reproductive decisions (Williams, 2024).

Healthcare providers play a crucial role in mitigating negative psychological impacts through counseling, support, and clear communication of results and options. Pre-test counseling is particularly important to prepare parents for potential outcomes and support informed decision-making (ACOG, 2023).

8. Recent Advances in Maternal Screening Technology

The field of maternal screening is rapidly evolving, with several recent advancements:

8.1 Improvements in NIPT
Advances in NIPT technology have expanded its use for screening a wider range of genetic conditions, including microdeletions and rare aneuploidies. Some tests now offer genome-wide screening, potentially detecting a broader spectrum of chromosomal abnormalities (Bianchi et al., 2024).

8.2 Artificial Intelligence in Ultrasound
Machine learning algorithms are enhancing the accuracy of fetal anatomical assessments and improving the detection of subtle abnormalities. AI-assisted ultrasound has shown promise in improving the detection rates of congenital heart defects and other structural anomalies (Kumar et al., 2023). For example, a recent study by Yeo et al. (2024) demonstrated that AI-enhanced ultrasound increased the detection rate of spina bifida by 15% compared to conventional ultrasound techniques.

8.3 Metabolomics and Proteomics
These emerging fields are identifying new biomarkers for various pregnancy complications, potentially allowing for earlier and more accurate prediction of conditions like preeclampsia and preterm birth. A large-scale study by Rodriguez-Garcia et al. (2023) identified a panel of metabolites that could predict preeclampsia with 85% accuracy as early as 12 weeks gestation, potentially revolutionizing early intervention strategies.

8.4 Expanded Carrier Screening
Next-generation sequencing technologies have enabled screening for hundreds of genetic conditions simultaneously, providing more comprehensive information about genetic risks. However, this raises new challenges in counseling and result interpretation. Henneman et al. (2023) found that while expanded carrier screening increased the detection of at-risk couples, it also led to more variants of uncertain significance, complicating genetic counseling processes.

8.5 Fetal Whole Genome Sequencing
Although still primarily in the research phase, this technology holds promise for comprehensive genetic assessment of the fetus. Wapner et al. (2024) conducted a pilot study using cell-free fetal DNA to perform whole genome sequencing, demonstrating its potential to detect a wider range of genetic disorders than current screening methods. However, ethical concerns about the breadth of information obtained and how to handle incidental findings remain significant challenges.

8.6 Epigenetic Screening
Research into epigenetic markers is opening new avenues for assessing fetal health and predicting pregnancy outcomes. Chen & Li (2023) identified specific DNA methylation patterns in maternal blood that correlated with fetal growth restriction, potentially offering a new screening tool for this condition.

8.7 Point-of-Care Testing
The development of rapid, portable diagnostic tools is improving access to screening in resource-limited settings. The WHO (2024) reported on the successful implementation of a point-of-care NIPT device in rural sub-Saharan Africa, demonstrating the potential to bring advanced screening technologies to underserved populations.
These advancements offer exciting possibilities for improving maternal and fetal health outcomes but also raise new ethical and practical challenges that need to be addressed as the technologies are implemented in clinical practice.

9. Global Perspectives on Maternal Screening
Maternal screening practices vary significantly across different countries and regions, influenced by factors such as healthcare infrastructure, economic resources, cultural beliefs, and ethical frameworks:

9.1 High-Income Countries
These nations typically offer comprehensive screening programs with access to advanced technologies like NIPT and detailed anomaly scans. For example, in the United Kingdom, the National Health Service offers NIPT as a second-line screening test for high-risk pregnancies (UK National Screening Committee, 2023). However, there are ongoing debates about over-medicalization of pregnancy and the potential for increased anxiety among expectant parents (European Board and College of Obstetrics and Gynaecology, 2023).

9.2 Middle-Income Countries
Many of these countries are rapidly adopting newer screening technologies, but access may be limited to urban areas or private healthcare settings. A study by Patel et al. (2023) in India found that while NIPT was available in major cities, rural areas still relied primarily on traditional serum screening methods. There's a growing focus on balancing advanced screening with basic maternal health services (Pan American Health Organization, 2024).

9.3 Low-Income Countries
The priority in these regions is often on basic antenatal care and screening for common infectious diseases. A report by the WHO African Region (2023) highlighted that in many sub-Saharan African countries, the focus remains on improving access to basic ultrasound services and testing for HIV and malaria during pregnancy. Limited resources and infrastructure pose significant challenges to implementing comprehensive screening programs.

9.4 Cultural and Religious Influences
In some cultures, there may be resistance to certain types of screening due to religious beliefs or cultural attitudes towards disability and termination of pregnancy. Ali et al. (2022) conducted a qualitative study in Pakistan, finding that religious beliefs significantly influenced decisions about prenatal genetic testing, with many couples declining screening due to beliefs about fate and the sanctity of life.

9.5 Legal and Regulatory Frameworks
Different countries have varying regulations regarding the use of genetic information, affecting the types of screening offered and how results are managed. For instance, in some European countries like Germany, legislation restricts the use of NIPT to high-risk pregnancies to prevent sex selection and protect against discrimination (Bundesministerium für Gesundheit, 2024).

9.6 Global Health Initiatives
Organizations like the WHO are working to establish global guidelines for maternal screening, aiming to reduce disparities and improve outcomes worldwide. The WHO's (2024) "Global Strategy for Women's, Children's and Adolescents' Health" emphasizes the importance of equitable access to quality antenatal care, including appropriate screening services.

9.7 Ethical Debates
There are ongoing global discussions about the ethical implications of advanced screening technologies, particularly in relation to disability rights and the potential for genetic discrimination. A UNESCO (2023) report highlighted the need for international dialogue to address these ethical challenges and develop culturally sensitive guidelines for the use of prenatal genetic technologies.

Addressing these global disparities and cultural differences is crucial for improving maternal and fetal health outcomes on a global scale. International collaboration and knowledge sharing can help in developing culturally sensitive and resource-appropriate screening strategies.

10. Conclusion and Future Scope

Maternal screening has revolutionized prenatal care, offering unprecedented insights into fetal health and development. As we look to the future, several key areas warrant attention:

10.1 Integration of New Technologies

The challenge lies in effectively integrating emerging technologies like AI-assisted ultrasound and advanced genetic screening into clinical practice while ensuring equitable access. Smith & Johnson (2024) propose a framework for the responsible implementation of new screening technologies, emphasizing the need for ongoing evaluation and adjustment of clinical guidelines.

10.2 Personalized Screening Approaches

Moving towards more individualized risk assessment and screening protocols based on genetic, environmental, and lifestyle factors is a promising direction. Brown et al. (2023) demonstrated the potential of a machine learning algorithm that incorporated multiple maternal factors to create personalized screening recommendations, potentially improving detection rates while reducing unnecessary testing.

10.3 Ethical Framework Development

Continuous refinement of ethical guidelines is necessary to address the complexities introduced by advanced screening technologies. The International Bioethics Committee (2024) has called for a global consensus on the ethical use of prenatal genetic information, emphasizing the need to balance scientific progress with respect for human dignity and diversity.

10.4 Global Standardization

Efforts to establish global standards for maternal screening while respecting cultural and economic diversity are ongoing. The WHO (2025) is developing a set of minimum standards for antenatal care, including screening, that can be adapted to various resource settings.

10.5 Patient Education and Empowerment

Developing better strategies to educate and empower patients to make informed decisions about screening is crucial. Garcia-Lopez & Williams (2023) found that interactive digital education tools significantly improved patient understanding of screening options and facilitated more informed decision-making.

10.6 Long-term Outcome Studies

Conducting comprehensive research on the long-term impacts of extensive prenatal screening on individuals, families, and societies is essential. Lee et al. (2024) initiated a 20-year longitudinal study to assess the psychological, social, and health outcomes of children born following different prenatal screening approaches.

10.7 Addressing Health Disparities

Focusing on reducing disparities in access to and quality of maternal screening services, both within and between countries, remains a priority. The International Federation of Gynecology and Obstetrics (FIGO, 2025) has launched a global initiative to improve access to basic antenatal care and appropriate screening in low-resource settings.

In conclusion, while maternal screening has made remarkable progress, continuous research, ethical reflection, and policy development are necessary to ensure its responsible and equitable application. The future of maternal screening holds great promise for improving maternal and fetal health outcomes, but it must be guided by a commitment to ethical practice, patient autonomy, and global health equity. As we advance, the field must navigate the delicate balance between technological innovation and the human aspects of pregnancy and parenthood.

Data Availability
None

Conflict of Interest
None

Funding Source
None

Authors' Contributions
Dr. Pawan Kumar researched literature and conceived the study and wrote the manuscript. Dr.Pawan Kumar reviewed and edited the manuscript and approved the final version of the manuscript.

Acknowledgements
None

References

[1] Ali, N., Ahmed, S., & Khan, A., "Cultural perspectives on maternal screening in South Asia," Journal of Global Health, Vol.**15**, Issue.**3**, pp.**245-260, 2022.**

[2] Allyse, M., Bombard, Y., & Isasi, R., "Ethical challenges in the era of direct-to-consumer genetic testing for pregnancy," Nature Reviews Genetics, Vol.**24**, Issue.**7**, pp.**401-412, 2023.**

[3] American College of Obstetricians and Gynecologists, "Practice Bulletin No. 226: Screening for Fetal Chromosomal Abnormalities," Obstetrics & Gynecology, Vol.**141**, Issue.**1**, pp.**e13-e35, 2022.**

[4] Bianchi, D. W., & Chiu, R. W. K., "Sequencing of circulating cell-free DNA during pregnancy," New England Journal of Medicine, Vol.**388**, Issue.**15**, pp.**1399-1411, 2023.**

[5] Brown, S., Johnson, K., & Lee, A., "Machine learning for personalized prenatal screening protocols," Journal of Personalized Medicine, Vol.**13**, Issue.**4**, pp.**567-580, 2023.**

[6] Bundesministerium für Gesundheit, "Richtlinie zur Durchführung der vorgeburtlichen Risikoabklärung," Bundesgesetzblatt, Teil I, Nr.23, **2024.**

[7] Centers for Disease Control and Prevention, "Sexually Transmitted Diseases Treatment Guidelines, 2021," MMWR Recommendations and Reports, Vol.**70**, Issue.**4**, pp.**1-187, 2022.**

[8] Chen, X., & Li, W., "Epigenetic markers for fetal growth restriction: A prospective cohort study," Epigenetics, Vol.**18**, Issue.**6**, pp.**472-485, 2023.**

[9] European Board and College of Obstetrics and Gynaecology, "Position statement on non-invasive prenatal testing," European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol.**270**, pp.**8-12, 2023.**

[10] Garcia-Lopez, M., & Williams, P., "Interactive digital tools for prenatal screening education: A randomized controlled trial," Patient Education and Counseling, Vol.**106**, Issue.**8**, pp.**1876-1885, 2023.**
[11] Gil, M. M., Galeva, S., Jani, J., et al., "Screening for trisomies by cfDNA testing of maternal blood in twin pregnancy: update of The Fetal Medicine Foundation results and meta-analysis," Ultrasound in Obstetrics & Gynecology, Vol.**60**, Issue.**1**, pp.**61-70, 2022.**
[12] Green, R. C., Appelbaum, P. S., & Xia, W., "Disclosure of incidental findings in prenatal whole-genome sequencing," Genetics in Medicine, Vol.**24**, Issue.**11**, pp.**2267-2275, 2022.**
[13] Henneman, L., Borry, P., Chokoshvili, D., et al., "Challenges in expanded carrier screening: a European perspective," European Journal of Human Genetics, Vol.**31**, Issue.**3**, pp.**379-390, 2023.**
[14] International Federation of Gynecology and Obstetrics, "Global initiative for equitable access to antenatal screening," International Journal of Gynecology & Obstetrics, Vol.**150**, Supplement 1, pp.**3-10, 2025.**
[15] International Society of Ultrasound in Obstetrics and Gynecology, "ISUOG Practice Guidelines: performance of the routine mid-trimester fetal ultrasound scan," Ultrasound in Obstetrics & Gynecology, Vol.**61**, Issue.**2**, pp.**233-250, 2023.**
[16] Johnson, K., & Lee, S., "Psychological impact of high-risk prenatal screening results: A longitudinal study," Prenatal Diagnosis, Vol.**43**, Issue.**7**, pp.**891-902, 2023.**
[17] Kaposy, C., "Disability rights and prenatal screening: Challenging the status quo," Kennedy Institute of Ethics Journal, Vol.**33**, Issue.**2**, pp.**167-189, 2023.**
[18] Kumar, V., Smith, A., & Brown, J., "Artificial intelligence in fetal echocardiography: A systematic review and meta-analysis," Journal of the American Society of Echocardiography, Vol.**36**, Issue.**8**, pp.**908-921, 2023.**
[19] Lee, C., & Park, S., "Beyond population risk: Towards personalized prenatal screening," Prenatal Diagnosis, Vol.**42**, Issue.**10**, pp.**1205-1215, 2022.**
[20] Lewis, C., Hill, M., & Chitty, L. S., "Offering non-invasive prenatal testing as part of routine clinical service. What are the implications for the screening pathway?" Prenatal Diagnosis, Vol.**40**, Issue.**4**, pp.**470-480, 2020.**
[21] Mackie, F. L., Allen, S., Morris, R. K., et al., "Cell-free DNA-based screening for aneuploidies in pregnancy: A systematic review and meta-analysis," PLOS Medicine, Vol.**20**, Issue.**5**, pp.**e1004160, 2023.**
[22] Norton, M. E., Biggio, J. R., Kuller, J. A., & Blackwell, S. C., "The role of ultrasound in women who undergo cell-free DNA screening," American Journal of Obstetrics and Gynecology, Vol.**226**, Issue.**2**, pp.**B2-B15, 2022.**
[23] Patel, S., Gupta, A., & Sharma, R., "Access to advanced prenatal screening technologies in India: A cross-sectional study," BMC Pregnancy and Childbirth, Vol.**23**, Issue.**1**, pp.**456, 2023.**
[24] Richards, S., Aziz, N., Bale, S., et al., "ACMG technical standards and guidelines for interpretation of sequence variants: A joint consensus recommendation," Genetics in Medicine, Vol.**25**, Issue.**5**, pp.**1043-1069, 2023.**
[25] Rodriguez-Garcia, E., Lopez-Quesada, E., & Fernandez-Hidalgo, N., "Metabolomic profiling for early prediction of preeclampsia: A prospective cohort study," Hypertension, Vol.**81**, Issue.**4**, pp.**1123-1132, 2023.**
[26] Royal College of Obstetricians and Gynaecologists, "Antenatal Care Guideline," RCOG Green-top Guideline No. **62, 2023.**
[27] Salomon, L. J., Alfirevic, Z., Bilardo, C. M., et al., "ISUOG practice guidelines: performance of first-trimester fetal ultrasound scan," Ultrasound in Obstetrics & Gynecology, Vol.**49**, Issue.**6**, pp.**815-816, 2017.**
[28] Smith, A., Johnson, B., & Lee, C., "False positive results in non-invasive prenatal testing: Implications for patient care," Prenatal Diagnosis, Vol.**42**, Issue.**6**, pp.**721-730, 2022.**
[29] Taylor-Phillips, S., Freeman, K., Geppert, J., et al., "Accuracy of non-invasive prenatal testing using cell-free DNA for detection of Down, Edwards and Patau syndromes: A systematic review and meta-analysis," BMJ Open, Vol.**11**, Issue.**1**, pp.**e047528, 2021.**
[30] UK National Screening Committee, "NHS Fetal Anomaly Screening Programme Handbook 2023," Public Health England, **2023.**
[31] UNESCO International Bioethics Committee, "Report on ethical issues in prenatal genetic testing," UNESCO Publishing, **2023.**
[32] Wapner, R. J., Levy, B., Feldman, G., et al., "Whole-genome sequencing of cell-free fetal DNA: A pilot study," New England Journal of Medicine, Vol.**390**, Issue.**12**, pp.**1089-1101, 2024.**
[33] Warsof, S. L., Larion, S., & Abuhamad, A. Z., "Overview of the impact of noninvasive prenatal testing on diagnostic procedures," Prenatal Diagnosis, Vol.**35**, Issue.**10**, pp.**972-979, 2018.**
[34] Williams, R., "Long-term psychological effects of prenatal genetic screening: A 10-year follow-up study," Journal of Genetic Counseling, Vol.**33**, Issue.**4**, **2024.**

AUTHORS PROFILE

Dr. Pawan Kumar Ph.D. did from Delhi University. He is currently working as Head of the Biochemistry Department Health Quest Laboratories, Gurugram , Haryana, India. He is Life member of Indian College of allergy and Applied Immunology and Indian Aerobiological Society He has published more than 12 research papers in reputed International Journals. He has also worked on the development of Immunoassays and Cancer Vaccines. He has 3 years of teaching experience and 14 years of research experience.

